In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi.
The in vitro activity of the everninomicin antibiotic SCH 27899 against 17 isolates of Borrelia spp. was investigated. MICs ranged from 0.06 to 0.5 microg/ml. Time-kill studies with the B31 strain of B. burgdorferi demonstrated >/=3-log10-unit killing after 72 h with concentrations representing four times the MIC. The in vitro activity of four other newer antimicrobial agents, meropenem, cefepime, quinupristin-dalfopristin, and linezolid, was also tested against the B31 strain. Meropenem was the most potent of the latter agents, with an MIC of 0.125 microg/ml.
Dever
L L
LL
Medical Service, Veterans Affairs New Jersey Health Care System, East Orange, New Jersey 07018, USA. dever.lisa@east-orange.va.gov
Torigian
C V
CV
Barbour
A G
AG
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015748:Borrelia burgdorferi Group / Q000187:drug effects*; D002443:Ceftriaxone / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D013845:Thienamycins / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D013845:Thienamycins; C001202:evernimicin; D002443:Ceftriaxone; D000077731:Meropenem; D004318:Doxycycline